Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is advancing its pipeline of innovative gene and cell therapies, focusing on unmet medical needs in retinal diseases through its Modifier Gene Therapy Platform, as well as expanding its offerings with platforms for novel biologic therapies and inhaled vaccines. The potential for significantly positive outcomes is underscored by the strong efficacy and safety observed in the ongoing Phase I/II study of OCU400 for inherited retinal diseases, which could enhance the company's market position. Additionally, attractive collaboration agreements and opportunities for mergers and acquisitions (M&A) present further upside potential for Ocugen's growth and financial performance.

Bears say

Ocugen Inc. faces a negative outlook primarily due to its inability to secure necessary investment, which the company attributes to adverse market conditions and a tight timeline for compliance with Nasdaq requirements. Furthermore, the anticipation of new treatments for retinal diseases could potentially render Ocugen's therapies non-competitive or obsolete, jeopardizing the future viability of its pipeline. Overall, these factors contribute to concerns regarding the company's capacity to advance its innovative gene and cell therapies in a challenging financial environment.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.